AARD SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026

Faruqi & Faruqi is investigating potential securities-law claims against Aardvark Therapeutics (NASDAQ: AARD) and notes that a federal class action has been filed. Investors who bought shares in or traceable to Aardvark's February 13, 2025 IPO, or held securities from February 13, 2025 through May 14, 2026, have until October 13, 2026 to seek lead-plaintiff status.

Analysis

This is not an independently verified operating development; plaintiff-law-firm outreach has little standalone information value and should not be treated as evidence of liability or an earnings impairment. The near-term effect is primarily technical: renewed litigation headlines can widen AARD's bid-ask spread, reduce marginal long-only demand, and pressure valuation if investors assign a higher probability to management-credibility damage ahead of the next clinical or commercial update.

The relevant exposure is not the ultimate settlement amount—typically immaterial for a biotech of this scale unless insurance coverage is constrained—but discovery risk. A complaint that survives dismissal could surface adverse information about trial design, regulatory interactions, launch assumptions, or prior disclosures, creating a 6-18 month overhang and raising the equity-risk premium. Conversely, dismissal, a quiet insurer-funded settlement, or subsequent data that validates the underlying asset would remove this discount; litigation deadlines themselves are not fundamental catalysts.

Consensus often overreacts to the word "class action" in thinly traded biotech while underweighting the possibility that the suit follows a genuine information event already reflected in the share price. Without the complaint, the alleged corrective disclosures, cash runway, short interest, and upcoming clinical/regulatory calendar, there is insufficient basis for a directional fundamental trade. The better setup is to monitor whether the stock breaks below the post-allegation low on materially elevated volume and whether borrow availability tightens—signals that the legal headline is becoming a persistent financing or credibility issue rather than transient noise.

Key Decisions for Investors

• No new directional position solely on this notice. Require the filed complaint and identified corrective-disclosure dates before underwriting legal damages, management-scienter risk, or any revenue/approval impact.
• For existing AARD longs, reduce position sizing into the October 13 lead-plaintiff deadline only if liquidity deteriorates; use the next earnings or clinical update—not the procedural deadline—as the decision catalyst. Reassess if management cuts cash-runway guidance, delays a program, or identifies regulatory correspondence omitted from prior disclosures.
• Set a short/watch alert rather than initiate: consider a tactical 1-3 month short only if AARD closes below its prior post-news low on at least 2x average volume and borrow remains available. Cover on a dismissal-related filing, constructive clinical data, or recovery above that breakdown level; biotech headline squeezes make unhedged shorts asymmetric.
• If options liquidity exists, incumbent holders can evaluate 2-4 month downside put spreads around the next fundamental catalyst rather than selling into a legal headline. The hedge is justified only when implied volatility is below the expected event move; otherwise premium likely exceeds the litigation-specific risk.